Huyabio International, Llc.

This early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic cancer) that have a specific genetic mutation called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves through the body. About…

This study tests a single intravenous dose of HBI 3000 in 150 adults aged 18-80 who have had atrial fibrillation (an irregular heartbeat) for less than 72 hours. The goal is to see if the drug can safely and quickly convert the heart back to a normal rhythm. The trial first finds…

This early-phase study tests an experimental oral drug, HBI-2376, in 42 adults with advanced solid tumors (lung, colon, pancreatic, or other) that have KRAS or EGFR mutations and have stopped responding to standard treatments. The main goals are to find the safest dose and unders…

This phase 3 study tests whether adding the drug HBI-8000 to the standard immunotherapy nivolumab works better than nivolumab alone for people with advanced melanoma that cannot be removed by surgery or has spread. About 450 adults with melanoma not previously treated with PD-1 o…